Molecular underpinnings of enzalutamide resistance.

Prostate cancer (PCa) is among the most common adult malignancies, and the second leading cause of cancer-related death in men. As PCa is hormone-dependent, blockade of the androgen receptor (AR) signaling is an effective therapeutic strategy for men with advanced metastatic disease. The discovery of enzalutamide, a compound that effectively blocks the AR axis and its clinical application has led to a significant improvement in survival time. However, the effect of enzalutamide is not permanent, and resistance to treatment ultimately leads to development of lethal disease, for which there currently is no cure. This review will focus on the molecular underpinnings of enzalutamide resistance, bridging the gap between the preclinical and clinical research on novel therapeutic strategies for combating this lethal stage of prostate cancer.

[1]  L. Ellis,et al.  Epigenetic reprogramming: A key mechanism driving therapeutic resistance. , 2018, Urologic oncology.

[2]  Henry W. Long,et al.  A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer , 2018, Cell.

[3]  L. Elo,et al.  Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer. , 2018, Endocrine-related cancer.

[4]  C. Evans,et al.  Enzalutamide and metformin combination therapy to overcome autophagy resistance in castration resistant prostate cancer (CRPC): Current results from a phase I study. , 2018 .

[5]  O. Sartor,et al.  Metastatic Prostate Cancer. , 2018, The New England journal of medicine.

[6]  J. Ruland,et al.  AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide. , 2017, European urology.

[7]  F. Claessens,et al.  Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer , 2017, Molecular and Cellular Endocrinology.

[8]  A. Gao,et al.  Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells , 2017, Molecular Cancer Therapeutics.

[9]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. , 2017, European urology.

[10]  C. Magi-Galluzzi,et al.  Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer , 2017, eLife.

[11]  A. Houtsmuller,et al.  Structure of the homodimeric androgen receptor ligand-binding domain , 2017, Nature Communications.

[12]  S. Patterson,et al.  mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review , 2017, Targeted Oncology.

[13]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[14]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[15]  Tanya K. Day,et al.  Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. , 2016, Endocrine-related cancer.

[16]  Matti Nykter,et al.  Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.

[17]  T. Penning,et al.  Selective AKR1C3 Inhibitors Potentiate Chemotherapeutic Activity in Multiple Acute Myeloid Leukemia (AML) Cell Lines. , 2016, ACS medicinal chemistry letters.

[18]  Ian G. Mills,et al.  The role of glycans in the development and progression of prostate cancer , 2016, Nature Reviews Urology.

[19]  Ali Shojaie,et al.  Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer , 2016, Nature Communications.

[20]  Kam Y. J. Zhang,et al.  The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide , 2016, Molecular Cancer Therapeutics.

[21]  Jonathan Epstein,et al.  Grading of prostatic adenocarcinoma: current state and prognostic implications , 2016, Diagnostic Pathology.

[22]  R. Soong,et al.  The Warburg effect and drug resistance , 2016, British journal of pharmacology.

[23]  D. V. van Aalten,et al.  O-GlcNAc transferase inhibitors: current tools and future challenges. , 2016, Biochemical Society transactions.

[24]  Damien Y. Duveau,et al.  Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism , 2016, Oncotarget.

[25]  C. Collins,et al.  Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients , 2016, Genome Biology.

[26]  V. Arora,et al.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.

[27]  S. Ha,et al.  Divergent Androgen Receptor and Beta-Catenin Signaling in Prostate Cancer Cells , 2015, PloS one.

[28]  Ben S. Wittner,et al.  RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance , 2015, Science.

[29]  D. Neal,et al.  A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy , 2015, The Journal of pathology.

[30]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[31]  Yezi Zhu,et al.  Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. , 2015, Cancer research.

[32]  E. Ben-Jacob,et al.  Prostate Cancer and Neuroendocrine Differentiation: More Neuronal, Less Endocrine? , 2015, Front. Oncol..

[33]  Martin E. Gleave,et al.  Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.

[34]  V. Njar,et al.  Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. , 2015, Journal of medicinal chemistry.

[35]  Hua Yu,et al.  Revisiting STAT3 signalling in cancer: new and unexpected biological functions , 2014, Nature Reviews Cancer.

[36]  K. Vosseller,et al.  Cancer Metabolism and Elevated O-GlcNAc in Oncogenic Signaling* , 2014, The Journal of Biological Chemistry.

[37]  D. George,et al.  Copper signaling axis as a target for prostate cancer therapeutics. , 2014, Cancer research.

[38]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[39]  R. Winterhalder,et al.  Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). , 2014, European urology.

[40]  Michael Kahn,et al.  Can we safely target the WNT pathway? , 2014, Nature Reviews Drug Discovery.

[41]  A. Tewari,et al.  Inflammation and prostate cancer: the role of interleukin 6 (IL‐6) , 2014, BJU international.

[42]  A. Gao,et al.  Upregulation of glucose metabolism by NF-κB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. , 2014, Endocrine-related cancer.

[43]  Yezi Zhu,et al.  Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.

[44]  H. Kung,et al.  Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model , 2014, Oncogene.

[45]  Heather H. Cheng,et al.  Glucocorticoids and prostate cancer treatment: friend or foe? , 2014, Asian journal of andrology.

[46]  Zhiyong Guo,et al.  Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy , 2014, Oncotarget.

[47]  崇行 上垣内.  Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients（前立腺癌細胞におけるO-GlcNAcの過剰発現は前立腺患者の予後不良と密接に関連している） , 2014 .

[48]  J. Epstein,et al.  Small cell carcinoma of the prostate , 2014, Nature Reviews Urology.

[49]  Wun-Jae Kim,et al.  Diagnosis of bladder cancer and prediction of survival by urinary metabolomics , 2014, Oncotarget.

[50]  K. Moon,et al.  Prostate cancer bone metastases acquire resistance to androgen deprivation via WNT5A-mediated BMP-6 induction , 2014, British Journal of Cancer.

[51]  Yezi Zhu,et al.  Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells , 2014, The Prostate.

[52]  H. Shimojo,et al.  Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients , 2013, Prostate Cancer and Prostatic Disease.

[53]  D. Zheng,et al.  Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade , 2013, Cell.

[54]  S. Moreno,et al.  Multiple functions of the noncanonical Wnt pathway. , 2013, Trends in genetics : TIG.

[55]  S. Taneja,et al.  Re: Abiraterone in metastatic prostate cancer without previous chemotherapy. , 2013, The Journal of urology.

[56]  Joshua M. Korn,et al.  An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). , 2013, Cancer discovery.

[57]  Gang Shao,et al.  A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. , 2013, Cancer discovery.

[58]  C. Logothetis,et al.  Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. , 2013, Cancer discovery.

[59]  P. Courtoy,et al.  Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone‐resistant prostate cancer cells and confer resistance to apoptosis , 2013, The Prostate.

[60]  V. Arora,et al.  Overcoming mutation-based resistance to antiandrogens with rational drug design , 2013, eLife.

[61]  K. Ovaska,et al.  FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. , 2013, Cancer research.

[62]  D. Ruderman,et al.  Anterior gradient 2 (AGR2): Blood‐based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype , 2013, The Prostate.

[63]  K. Silverstein,et al.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. , 2013, Cancer research.

[64]  M. Rubin,et al.  New Strategies in Prostate Cancer: Translating Genomics into the Clinic , 2012, Clinical Cancer Research.

[65]  J. Schalken,et al.  Aldo-keto Reductase Family 1 Member C3 (AKR1C3) Is a Biomarker and Therapeutic Target for Castration-Resistant Prostate Cancer , 2012, Molecular medicine.

[66]  F. Giles,et al.  Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO‐dependent mechanism , 2012, International journal of cancer.

[67]  Robert H. Bell,et al.  From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer , 2012, The Journal of pathology.

[68]  M. Reginato,et al.  Critical Role of O-Linked β-N-Acetylglucosamine Transferase in Prostate Cancer Invasion, Angiogenesis, and Metastasis* , 2012, The Journal of Biological Chemistry.

[69]  P. Troncoso,et al.  Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features , 2011, Clinical Cancer Research.

[70]  P. Nelson,et al.  Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. , 2011, Cancer research.

[71]  M. V. Vander Heiden,et al.  Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. , 2011, Annual review of cell and developmental biology.

[72]  Yuehua Wu,et al.  AMPK-mediated autophagy is a survival mechanism in androgen-dependent prostate cancer cells subjected to androgen deprivation and hypoxia. , 2011, Cellular signalling.

[73]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[74]  M. Gerstein,et al.  Molecular characterization of neuroendocrine prostate cancer (NEPC) and identification of new drug targets. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  P. Chambon,et al.  Noncanonical Wnt signaling mediates androgen-dependent tumor growth in a mouse model of prostate cancer , 2011, Proceedings of the National Academy of Sciences.

[76]  J. Schalken,et al.  Steroidogenic Enzymes and Stem Cell Markers Are Upregulated during Androgen Deprivation in Prostate Cancer , 2011, Molecular medicine.

[77]  Kevin Bray,et al.  Targeting tumor metabolism with 2‐deoxyglucose in patients with castrate‐resistant prostate cancer and advanced malignancies , 2010, The Prostate.

[78]  N. Socci,et al.  Inaugural Article: Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor , 2010 .

[79]  D. Guertin,et al.  Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy , 2010, Oncogene.

[80]  David E. Williams,et al.  Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. , 2010, Cancer cell.

[81]  J. Pinski,et al.  Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer , 2010, Clinical Cancer Research.

[82]  Y. DeClerck,et al.  Interleukin-6 in bone metastasis and cancer progression. , 2010, European journal of cancer.

[83]  F. Claessens,et al.  The rules of DNA recognition by the androgen receptor. , 2010, Molecular endocrinology.

[84]  A. Farooque,et al.  Enhancement of radiation and chemotherapeutic drug responses by 2-deoxy-D-glucose in animal tumors. , 2009, Journal of cancer research and therapeutics.

[85]  Rajiv Sarin,et al.  Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. , 2009, Journal of cancer research and therapeutics.

[86]  M. Dowsett,et al.  Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  F. Sotgia,et al.  An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease spread and epithelial Akt activation , 2009, Cell cycle.

[88]  T. Penning,et al.  Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. , 2009, Chemico-biological interactions.

[89]  M. Gleave,et al.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.

[90]  N. Smith,et al.  Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism. , 2008, The Journal of urology.

[91]  G. Gao,et al.  Autophagy protects LNCaP cells under androgen deprivation conditions , 2008, Autophagy.

[92]  R. Marchase,et al.  HEXOSAMINE BIOSYNTHESIS AND PROTEIN O-GLYCOSYLATION: THE FIRST LINE OF DEFENSE AGAINST STRESS, ISCHEMIA, AND TRAUMA , 2007, Shock.

[93]  T. Kodama,et al.  Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer , 2007, Journal of Clinical Pathology.

[94]  Frank Claessens,et al.  The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. , 2007, Cancer research.

[95]  Ximing J. Yang,et al.  Tumor suppressor activity of glucocorticoid receptor in the prostate , 2007, Oncogene.

[96]  A. Evans,et al.  Large Cell Neuroendocrine Carcinoma of Prostate: A Clinicopathologic Summary of 7 Cases of a Rare Manifestation of Advanced Prostate Cancer , 2006, The American journal of surgical pathology.

[97]  K. Kihara,et al.  Glucocorticoids Suppress Tumor Angiogenesis and In vivo Growth of Prostate Cancer Cells , 2006, Clinical Cancer Research.

[98]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[99]  J. Pitha,et al.  Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. , 2006, Endocrine-related cancer.

[100]  R. Franklin,et al.  Altered metabolism and mitochondrial genome in prostate cancer , 2006, Journal of Clinical Pathology.

[101]  Georg Bartsch,et al.  Interleukin‐6 regulation of prostate cancer cell growth , 2005, Journal of cellular biochemistry.

[102]  P. Kantoff,et al.  The Prognostic Significance of Plasma Interleukin-6 Levels in Patients with Metastatic Hormone-Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 9480 , 2005, Clinical Cancer Research.

[103]  P. Abrahamsson,et al.  Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. , 2005, European urology.

[104]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[105]  R. Nusse,et al.  The Wnt signaling pathway in development and disease. , 2004, Annual review of cell and developmental biology.

[106]  A. Potti,et al.  Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. , 2004, Cancer.

[107]  F. Claessens,et al.  Differential effect of small ubiquitin-like modifier (SUMO)-ylation of the androgen receptor in the control of cooperativity on selective versus canonical response elements. , 2004, Molecular endocrinology.

[108]  F. Claessens,et al.  Structural basis of androgen receptor binding to selective androgen response elements. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[109]  H. Jabbour,et al.  Expression, localization, and signaling of prostaglandin F2 alpha receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor and mitogen-activated protein kinase signaling pathways. , 2004, The Journal of clinical endocrinology and metabolism.

[110]  K. Akakura,et al.  Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. , 2002, The Journal of urology.

[111]  M. Kattan,et al.  Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. , 2001, Urology.

[112]  N Nonomura,et al.  Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. , 2001, Journal of the National Cancer Institute.

[113]  D. Tindall,et al.  Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.

[114]  E. Keller,et al.  Interleukin-6 and prostate cancer progression. , 2001, Cytokine & growth factor reviews.

[115]  W. Isaacs,et al.  Detection and analysis of β‐catenin mutations in prostate cancer , 2000 .

[116]  R. Franklin,et al.  The Intermediary Metabolism of the Prostate: A Key to Understanding the Pathogenesis and Progression of Prostate Malignancy , 2000, Oncology.

[117]  F. Claessens,et al.  Differences in DNA Binding Characteristics of the Androgen and Glucocorticoid Receptors Can Determine Hormone-specific Responses* , 2000, The Journal of Biological Chemistry.

[118]  F. Claessens,et al.  Differential DNA binding by the androgen and glucocorticoid receptors involves the second Zn-finger and a C-terminal extension of the DNA-binding domains. , 1999, The Biochemical journal.

[119]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.

[120]  P. Abrahamsson.  Neuroendocrine differentiation in prostatic carcinoma , 1999, The Prostate.

[121]  Akira,et al.  Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. , 1998, Journal of biochemistry.

[122]  R. Franklin,et al.  Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer , 1998, The Prostate.

[123]  D. Peehl,et al.  Expression and Characterization of Recombinant Type 2 3α-Hydroxysteroid Dehydrogenase (HSD) from Human Prostate: Demonstration of Bifunctional 3α/17β-HSD Activity and Cellular Distribution , 1997 .

[124]  D. Osoba,et al.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[125]  J. Buckner,et al.  Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone‐refractory metastatic prostate carcinoma , 1995, Cancer.

[126]  F. Johnson,et al.  Small cell carcinoma of the prostate , 1991, Cancer.

[127]  P. di Sant'Agnese,et al.  Neuroendocrine differentiation in prostatic carcinoma. , 1987, Human pathology.

[128]  M. Gleave,et al.  Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. , 2018, European urology.

[129]  C. Roberts.  IGF-1 and prostate cancer. , 2004, Novartis Foundation symposium.

[130]  A. Potti,et al.  Up‐regulation of Wnt‐1 and β‐catenin production in patients with advanced metastatic prostate carcinoma , 2004 .

[131]  L. Collette,et al.  Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.